<DOC>
	<DOCNO>NCT00291668</DOCNO>
	<brief_summary>This multi-centre , randomize , double-blind , dose response clinical study CDP870 patient Crohn 's disease .</brief_summary>
	<brief_title>Clinical Study CDP870/Certolizumab Pegol Patients With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients diagnose Crohn 's disease ( accord Crohn 's disease diagnostic criterion develop research group intractable inflammatory bowel disorder [ Shimoyama group , January 25 , 2002 ] ) least 24 week start date observation period Patients Crohn 's Disease Activity Index ( CDAI ) score range 220 450 inclusive observation period Creactive protein ( CRP ) 1 mg/dL high laboratory test perform start observation period Stoma patient Patients history severe hypersensitivity anphylactic reaction antiTNF alpha antibody Patients participate clinical study CDP870 Pregnant lactate patient , patient childbearing potential , patient attempt pregnancy study period Patients judged inappropriate enrollment principal investigator subinvestigators</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>CDP870 , Certolizumab pegol</keyword>
</DOC>